Fig. 4. Kaplan-Meier plots of new genomic risk factors in high-risk smoldering myeloma under treatment.

Biochemical progression-free survival curves of the 44 high-risk SMM cases were plotted based on the presence (red) or absence (black) of different alterations at baseline. The 13 ultrahigh-risk patients were not considered here. (A) KRAS mutations; (B) NRAS mutations; (C) concurrent FGFR3 mutation and t(4;14). The number of patients for each category is shown in brackets. bPFS biochemical progression-free survival SV structural variant, WT wild type.